Marker Therapeutics, Inc.

Category: Media Coverage

Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Non-Engineered T Cells to Prevent or Treat Relapse in Post-Transplant AML/MDS

Read More

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Researchers from Baylor College of Medicine and Texas Children’s Hospital are exploring “non-engineered” T-cell therapies that are easier to manufacture and able to target multiple antigens.
Read More

Houston: One of the Fastest-Growing Life Science Communities

A recent report by CBRE Research analyzing U.S. life science clusters found that Houston, Texas is the third-fastest growing life science market from 2014 to 2017.
Read More

Marker Therapeutics Rockets After CEO Says Phase 2 Leukemia Trial with T-cell Therapy in Works

With the help of Marker's technology, a population of T-cells attacks multiple cancer targets and works to activate a patient's immune system to trigger anti-tumor activity.
Read More

Marker Therapeutics: Phenomenal Data In Lymphoma And Other Indications, Yet Little Recognition From The Street

DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.
Read More

Cancer-Focused Marker Therapeutics Shares Rise After Update on Clinical Trial Pipeline

The Houston, Texas-based immuno-oncology group gave an update on five clinical trials.
Read More

Marker Therapeutics Exits ASH An Optimist. Should That Be Enough For You?

Marker Therapeutics has emerged out of a merger with Tapimmune to push forward new cell-based cancer vaccines.
Read More

DoD Awards $11M for Phase 2 Trial of TPIV110 Breast Cancer Therapy

The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy for women with HER2-positive breast cancer.
Read More

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune's ticker (TPIV).
Read More

Mayo Clinic Lands $11 Million Grant to Study Breast Cancer Immunotherapy

The Department of Defense awarded more than $11 million for this Jacksonville study.
Read More